Development of Dysplastic Nevi in a Child with LEPR Deficiency Treated with Setmelanotide
{{output}}
Setmelanotide is a recently approved medication for patients over two years of age with monogenic obesity that emerges from POMC, LEPR, PCSK1 mutations, or Bardet-Biedl syndrome. While primarily targeting melanocortin-4 receptors (MC4R), setmelanotide also wea... ...
